Sino-US biotech firm Laekna has announced that it has received clinical trial approval from the Center for Drug Evaluation (CDE) for its monoclonal antibody drug candidate, LAE102, intended for the treatment of obesity. This development follows the drug’s previous clinical trial approval in the US last month.
In-house developed, LAE102 is a potent and selective monoclonal antibody targeting ActRIIA, which has demonstrated its capacity to increase muscle mass and decrease fat in pre-clinical trials. The combination therapy of LAE102 with a GLP-1 receptor agonist is anticipated to further reduce fat while significantly mitigating muscle loss associated with the use of GLP-1 receptor agonists.- Flcube.com
